Plasma Derived Therapy Market Size

Plasma Derived Therapy Market Size

Plasma Derived Therapy Market size was valued over USD 16.8 billion in 2022 and will grow momentously at 7.5% CAGR between 2023 and 2032. Increasing prevalence of rare diseases including primary immunodeficiency diseases, idiopathic thrombocytopenic purpura (ITP), von Willebrand disease, and others are one of the major factors contributing to the growth of market across the globe. The higher incidence rate of primary immunodeficiency diseases and von Willebrand disease that can lead to severe health conditions will drive the demand for plasma derived therapy.

To get key market trends

  Download Free Sample

According to the report published by the Centres for Disease Control and Prevention in 2021, around 3.2 million people in U.S. suffer from von Willebrand disease. Hence, the availability of effective plasma derived therapy that offers effective solution against these rare diseases will lead to unprecedented growth opportunities to the plasma derived therapy industry in the forthcoming years.
 

Plasma-derived therapy is a highly effective treatment derived from human plasma that is widely used to treat rare and complex diseases. Plasma-derived therapies aid in the replacement of deficient or missing proteins, allowing people to live healthier and more productive lives. Plasma-derived products primarily consist of coagulation factors, albumin, and immunoglobulins, that are used as life-saving therapeutics to treat variety of genetic and life-threatening diseases worldwide.